AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics expects to use its disease-specific focus and technological approach to identify and advance drugs that will provide significant therapeutic benefits for LAM patients. AI Therapeutics develops drugs for rare diseases and cancer. LAM takes advantage of the inflection point in biological understanding and computer science, leveraging big data from NextGen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.

Ohara Pharmaceutical Co., Ltd. manufactures, distributes, imports, and exports pharmaceuticals and related food additives. It also specializes in orphan drugs for Leukemia, Leukocytpenia, stem cell transplantation, and Parkinson's disease. The company was founded on November 5, 1964 and is headquartered in Koka, Japan.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Yunnan Keats Regenerative Medicine Research Institute Co., Ltd., established on 2018-01-08, Business scope includes research on stem cell biotechnology,Development and technology transfer;Stem Cell Storage Technology Services;stem cell collection,detection,to prepare,Freezing and Serving;immune cell technology,Research on Medical Testing Technology,to develop,technology transfer,technical consulting;medical service;Health Information Consultation,Business Management Consulting;cosmetic,Medical Device Research,development and production;Domestic Trade,Material supply and marketing;Genetic Testing Technology Consulting;Genetic data analysis service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.

Yunnan Meiyan Meiling Biotechnology Co., Ltd., established on 2017-06-07, Business scope includes general items:Medical Research and Experimental Development;R&D and application of cell technology;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export;Domestic trade agent;Cosmetics Wholesale;Cosmetics Retail;software development;Corporate Image Planning;Information Consulting Service(Not including licensing information consulting services);(Test and trial production activities involving the use of dangerous substances are strictly prohibited;Dangerous chemicals are strictly prohibited,Ammonia-related refrigeration industry and national restricted prohibited products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Medecine & Innovation SARL is a private company headquartered in Paris, France. The firm provides educational support services.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.